To address the growing demand for complex modalities, Samsung Biologics is advancing its capabilities to support global biopharma with flexibility and scale.
In a recent interview with Nikkei Biotechnology & Business, Kevin Sharp, Executive Vice President and Head of Sales & Operation, shared how the company is geared to drive innovation.
Key highlights include:
- Samsung Biologics' end-to-end ADC capabilities for clients' diverse pipelines
- Key features of the new ADC facility and suite of service offerings
- Samsung Biologics' continued capacity expansion and enhanced flexibility
To address the growing demand for complex modalities, Samsung Biologics is advancing its capabilities to support global biopharma with flexibility and scale.
In a recent interview with Nikkei Biotechnology & Business, Kevin Sharp, Executive Vice President and Head of Sales & Operation, shared how the company is geared to drive innovation.
Key highlights include:
- Samsung Biologics' end-to-end ADC capabilities for clients' diverse pipelines
- Key features of the new ADC facility and suite of service offerings
- Samsung Biologics' continued capacity expansion and enhanced flexibility
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article